Semaglutide Reduces Liver Fibrosis and Improves Heart Health in High-Risk Patients
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a global health concern often progressing to liver fibrosis and significantly increasing the risk of cardiovascular disease (CVD). While GLP-1 receptor agonists like semaglutide are well-established for weight loss and glycemic control, their direct impact on liver fibrosis progression and associated cardiovascular outcomes in patients specifically at high risk for liver disease has remained less understood. This study investigated whether semaglutide could mitigate liver fibrosis and improve heart outcomes in a population identified as having a high risk of advanced liver fibrosis.
Results
The analysis revealed significant and clinically meaningful benefits of semaglutide in patients at high risk of liver fibrosis. Treatment with semaglutide led to a significant reduction in markers of liver fibrosis, with the FIB-4 index showing an average 18% decrease from baseline compared to only a 3% decrease in the placebo group (p<0.001). Similarly, the enhanced liver fibrosis (ELF) score, another key indicator of fibrosis severity, improved by 15% in the semaglutide group versus a 2% improvement in the placebo group (p<0.001). These improvements suggest a direct positive effect on liver health. The most important finding was a 20% reduction in the risk of major adverse cardiovascular events (MACE) in the semaglutide group compared to placebo (Hazard Ratio 0.80, 95% CI 0.72-0.90, p<0.001) specifically among patients with high liver fibrosis risk, mirroring the overall SELECT trial results. This indicates that semaglutide not only impacts liver health but also confers substantial cardiovascular protection in this vulnerable population.
Why It Matters
This study provides compelling evidence that semaglutide offers a dual therapeutic benefit, simultaneously addressing liver fibrosis and cardiovascular risk in patients already at high risk for advanced liver disease. The findings suggest that GLP-1 receptor agonists could play a crucial role in managing the complex interplay between metabolic dysfunction, liver disease, and heart health, particularly in a population with significant unmet medical needs. These results strongly support the potential for semaglutide to be used as a treatment strategy for patients with MASLD/NAFLD and significant fibrosis, especially those with co-existing cardiovascular disease. Future dedicated clinical trials focusing on MASLD progression and regression, potentially with liver biopsy endpoints, are warranted to solidify these findings and inform new treatment guidelines.